The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The CaDAnCe-104 trial of BGB-16673 in combination with other agents in R/R B-cell malignancies
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses the CaDAnCe-104 trial (NCT06634589), an ongoing, open-label, phase Ib/II study of BTK degrader BGB-16673 in combination with other agents in patients with relapsed/refractory (R/R) B-cell malignancies. Dr Cheah highlights that the study involves multiple sub-studies, including combinations with zanubrutinib, sonrotoclax, glofitamab, and mosunetuzumab. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CaDAnCe-104 is actually a trials-in-progress abstract, so we don’t actually have any data to share at this meeting, but really it’s an overview of a multi-cohort study in patients with relapsed and refractory B-cell malignancies evaluating the BTK degrader BGB-16673 in combination with a range of partners. There’s a sub-study involving zanubrutinib, sonrotoclax, which is the BCL2 inhibitor, a combination with glofitamab, which is a CD20-CD3 bispecific antibody, and mosunetuzumab, which is another CD20-CD3 bispecific antibody...
CaDAnCe-104 is actually a trials-in-progress abstract, so we don’t actually have any data to share at this meeting, but really it’s an overview of a multi-cohort study in patients with relapsed and refractory B-cell malignancies evaluating the BTK degrader BGB-16673 in combination with a range of partners. There’s a sub-study involving zanubrutinib, sonrotoclax, which is the BCL2 inhibitor, a combination with glofitamab, which is a CD20-CD3 bispecific antibody, and mosunetuzumab, which is another CD20-CD3 bispecific antibody. So there are varying cohorts across a range of different B-cell malignancy subtypes with dose escalation and the trial is currently ongoing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
